Spots Global Cancer Trial Database for Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab
Official Title: Response to Influenza Vaccination in Lymphoma Patients Treated With CHOP and Rituximab
Study ID: NCT01707628
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to compare the number of responders to vaccination with the influenza virus vaccine at different time points after last dose of rituximab in patients with lymphoma. Secondly to study the immune-response to vaccination with influenza virus vaccine, after treatment with rituximab in relation to the reconstitution of immune-function.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Medisch Centrum Leeuwarden, Leeuwarden, Friesland, Netherlands
Canisius Wilhelmina Hospital, Nijmegen, Gelderland, Netherlands
Onze Lieve Vrouwen Gasthuis, Amsterdam, Noord-Holland, Netherlands
Medisch Spectrum Twente, Enschede, Overrijssel, Netherlands
St. Antonius Hospital, Nieuwegein, Utrecht, Netherlands
Reinier de Graaf Groep, Delft, Zuid-Holland, Netherlands
Albert Schweitzer Hospital, Dordrecht, Zuid-Holland, Netherlands
Contact Details
Name: Minke AE Rab, Drs.
Affiliation: St. Antonius Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
